Dr. Reddy’s Laboratories is currently trading at Rs. 5538.60, up by 119.25 points or 2.20% from its previous closing of Rs. 5419.35 on the BSE.

The scrip opened at Rs. 5450.00 and has touched a high and low of Rs. 5572.20 and Rs. 5431.00 respectively. So far 6547 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 5986.20 on 24-Aug-2023 and a 52 week low of Rs. 4176.85 on 25-Jan-2023.

Last one week high and low of the scrip stood at Rs. 5572.20 and Rs. 5375.00 respectively. The current market cap of the company is Rs. 92874.16 crore.

The promoters holding in the company stood at 26.66%, while Institutions and Non-Institutions held 49.23% and 10.09% respectively.

Dr. Reddy’s Laboratories has rolled out Nerivio in India, a state-of-the-art United States Food and Drug Administration (USFDA) approved wearable therapy device for drug-free management of Migraine. Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migraine with or without aura for adults and adolescents aged 12 years and above.

Nerivio can be worn on the upper arm. Each device has in-built 18 x 45-minute treatment sessions. It is to be used within 60 minutes of onset of headache for acute treatment of migraine or every alternate day for prevention of migraine. The device uses the Remote Electrical Neuromodulation (REN) mechanism to specifically activate conditioned pain modulation by stimulating nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects the original source of migraine pain in the head.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.